

REMARKS

Claims 68 and 70 are amended and claims 71-75 are canceled herein. Support for the amendment is based, for example, on the description at pages 20-22 and the exemplary compounds of the specification. Claims 1-67 and 76-78 were previously canceled. Upon entry of the Amendment, claims 68-70 will be all of the claims pending.

I. Response to Claim Rejections - 35 U.S.C. § 112

A. Claims 70 and 72 are rejected under 35 U.S.C. §112, first paragraph, because the specification, while being enabling for a pharmaceutical composition that inhibits an EDG-2 receptor, allegedly does not reasonably provide enablement for inhibiting any LPA receptor or treating the disease of claim 72.

Claim 70 is amended herein by incorporating the subject matter of claim 71. That is, claim 70 is amended to recite that the LPA receptor is an EDG-2 receptor, thereby obviating the rejection.

Accordingly, Applicants respectfully request withdrawal of the rejection under 35 U.S.C. § 112, 1st paragraph.

B. Claims 68-72 are rejected under 35 U.S.C. § 112, second paragraph, as being indefinite. The Examiner states that the scope of the term “heterocyclic” as recited in the claims requires clarification.

Without conceding the merits of the rejection, claim 68 is amended herein to recite specific heterocyclic groups based on the exemplary compounds of the specification and the description at pages 20-22, thereby obviating the rejection.

Accordingly, Applicants respectfully request withdrawal of the rejection.

II. Response to Claim Rejection – Obviousness- Type Double Patenting

Claims 68-72 are provisionally rejected on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claim 1 of U.S. Patent Publication Application No. 2007/0149595.

Applicants respectfully defer responding until allowable subject matter is indicated by the Examiner. Applicants further note that the present application was earlier filed and if the only rejection remaining in this application is the provisional obviousness-type double patenting rejection, the Examiner should withdraw the rejection in this application and allow the present application to issue.

Accordingly, Applicants request withdrawal of the provisional obviousness-type double patenting rejection.

III. Conclusion

In view of the above, reconsideration and allowance of this application are now believed to be in order, and such actions are hereby solicited. If any points remain in issue which the Examiner feels may be best resolved through a personal or telephone interview, the Examiner is kindly requested to contact the undersigned at the telephone number listed below.

The USPTO is directed and authorized to charge all required fees, except for the Issue Fee and the Publication Fee, to Deposit Account No. 19-4880. Please also credit any overpayments to said Deposit Account.

Respectfully submitted,


SUGHRUE MION, PLLC
Telephone: (202) 293-7060
Facsimile: (202) 293-7860

WASHINGTON DC SUGHRUE/265550

65565

CUSTOMER NUMBER

Date: January 23, 2009


Susan J. Mack
Registration No. 30,951